(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
27 November 2014 (27.11.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/187922 A1

(51) International Patent Classification:
C07D 471/04 (2006.01) *A61P 35/00* (2006.01)
C07D 487/04 (2006.01) *A61P 37/00* (2006.01)
C07D 519/00 (2006.01) *A61P 29/00* (2006.01)
A61K 31/437 (2006.01) *A61P 25/00* (2006.01)
A61K 31/4985 (2006.01) *A61P 3/00* (2006.01)

(21) International Application Number:
PCT/EP2014/060586

(22) International Filing Date:
22 May 2014 (22.05.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
1309405.7 24 May 2013 (24.05.2013) GB
1402341.0 11 February 2014 (11.02.2014) GB

(71) Applicant: **IOMET PHARMA LTD.** [GB/GB]; Nine Edinburgh Bioquater, Little France Road, Edinburgh EH16 4UX (GB).

(72) Inventors: **COWLEY, Phillip Martin**; c/o TPP Global Development, Nine Edinburgh Bioquater, Little France Road, Edinburgh EH16 4UX (GB). **WISE, Alan**; c/o TPP Global Development, Nine Edinburgh Bioquater, Little France Road, Edinburgh EH16 4UX (GB). **BROWN, Thomas James**; c/o TPP Global Development, Nine Edinburgh Bioquater, Little France Road, Edinburgh EH16 4UX (GB). **ISHERWOOD, Matthew**; c/o AMRI, 61 Science Park Road, #05-01, Galen 117525 (SG). **CHAKRABARTI, Anjan**; c/o AMRI, 61 Science Park Road, #05-01, Galen 117525 (SG).

(74) Agent: **CHRISTOPHER MICHAEL HILL**; Page White & Farrer, Bedford House, John Street, London WC1N 2BF (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

(54) Title: SLC2A TRANSPORTER INHIBITORS



(I)

(57) Abstract: Provided is a SLC2A class I transporter inhibitor compound for use in medicine, which compound comprises the following formula (I): wherein A and Z may be the same or different and are each independently selected from C, N, O and S; each X may be the same or different and is independently selected from C, N, O and S; R^1 and R^5 may be present or absent and may be the same or different and are each selected from H and a substituted or unsubstituted organic group; Z completes a ring with each X, each ring comprising from 3 to 8 ring atoms including the X, A, and Z, each ring atom being independently selected from C, N, O and S, and each ring atom being unsubstituted or independently substituted with H or a substituted or unsubstituted organic group; and wherein the bonds between all of the atoms in the rings including the X, A, and Z may independently be single bonds or double bonds, provided that when X or a ring atom is O or S the bonds to X are single bonds.

WO 2014/187922 A1